Literature DB >> 6231141

In vitro reversal of fragile-X expression by exogenous thymidine.

G B Gardiner, S L Wenger, M W Steele.   

Abstract

A virtually thymidine free medium was used to test the effects of exogenous thymidine on lymphocyte expression of the fragile-X. De novo pathway thymidylic acid synthesis in the cells was blocked by FUdR. Our results suggest that in vitro exogenous thymidine is directly responsible for suppressing expression of the fragile-X. More importantly, delayed addition of exogenous thymidine can negate fragile-X expression after it has first been induced by FUdR.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231141     DOI: 10.1111/j.1399-0004.1984.tb00475.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  3 in total

1.  Fragile X syndrome: clinical, cytogenetic, biochemical and molecular features.

Authors:  J C Mixon; V G Dev
Journal:  Indian J Pediatr       Date:  1986 Jul-Aug       Impact factor: 1.967

2.  The fragile X syndrome in a large family. I. Cytogenetic and clinical investigations.

Authors:  H Veenema; J P Geraedts; G C Beverstock; P L Pearson
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

3.  Analysis of the fragile-X chromosome: localization and detection of the fragile site in high resolution preparations.

Authors:  M S Krawczun; E C Jenkins; W T Brown
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.